These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19304113)

  • 1. Properties of pathogen-inactivated plasma components.
    Prowse C
    Transfus Med Rev; 2009 Apr; 23(2):124-33. PubMed ID: 19304113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on pathogen reduction technology for therapeutic plasma: an overview.
    Solheim BG; Seghatchian J
    Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop.
    Klein HG; Glynn SA; Ness PM; Blajchman MA;
    Transfusion; 2009 Jun; 49(6):1262-8. PubMed ID: 19392769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Component pathogen inactivation: a critical review.
    Prowse CV
    Vox Sang; 2013 Apr; 104(3):183-99. PubMed ID: 23134556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogen inactivation technology: cleansing the blood supply.
    Klein HG
    J Intern Med; 2005 Mar; 257(3):224-37. PubMed ID: 15715679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogen reduction of blood components.
    Solheim BG
    Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of microbial contaminants of blood components.
    AuBuchon JP; Dodd RY
    Clin Lab Med; 1992 Dec; 12(4):787-803. PubMed ID: 1286565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products.
    Goodrich RP; Doane S; Reddy HL
    Biologicals; 2010 Jan; 38(1):20-30. PubMed ID: 20093041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogen inactivation: coming of age.
    Lozano M; Cid J
    Curr Opin Hematol; 2013 Nov; 20(6):540-5. PubMed ID: 24104416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Virus inactivated plasma].
    Köhler M; Wieding JU
    Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():73-6. PubMed ID: 8000259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials for pathogen reduction in transfusion medicine: a review.
    McClaskey J; Xu M; Snyder EL; Tormey CA
    Transfus Apher Sci; 2009 Dec; 41(3):217-25. PubMed ID: 19793679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the use of pathogen-reduced human plasma and platelet concentrates.
    Seltsam A; Müller TH
    Br J Haematol; 2013 Aug; 162(4):442-54. PubMed ID: 23710899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.
    Blajchman MA
    Transfus Clin Biol; 2009 May; 16(2):70-4. PubMed ID: 19427252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fresh-frozen plasma, pathogen-reduced single-donor plasma or bio-pharmaceutical plasma?
    Hellstern P
    Transfus Apher Sci; 2008 Aug; 39(1):69-74. PubMed ID: 18583192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of riboflavin for the inactivation of pathogens in blood products.
    Goodrich RP
    Vox Sang; 2000; 78 Suppl 2():211-5. PubMed ID: 10938955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogen inactivation: making decisions about new technologies - preliminary report of a consensus conference.
    Klein HG; Anderson D; Bernardi MJ; Cable R; Carey W; Hoch JS; Robitaille N; Sivilotti ML; Smaill F
    Vox Sang; 2007 Aug; 93(2):179-82. PubMed ID: 17683364
    [No Abstract]   [Full Text] [Related]  

  • 17. Bacterial risk reduction by improved donor arm disinfection, diversion and bacterial screening.
    McDonald CP
    Transfus Med; 2006 Dec; 16(6):381-96. PubMed ID: 17163869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogen reduction technique for fresh-frozen plasma, cryoprecipitate, and plasma fraction minipools prepared in disposable processing bag systems.
    Burnouf T; Radosevich M; El-Ekiaby M; Goubran H
    Transfusion; 2011 Feb; 51(2):446-7; author reply 447-8. PubMed ID: 21309785
    [No Abstract]   [Full Text] [Related]  

  • 19. 'Premium' plasma: isn't 'regular' blood safe enough?
    Consum Rep; 1999 Sep; 64(9):61-3. PubMed ID: 10848094
    [No Abstract]   [Full Text] [Related]  

  • 20. Pathogen inactivation of platelet concentrates and fresh frozen plasma.
    Jackson JE
    Br J Biomed Sci; 2003; 60(4):227-32. PubMed ID: 14725341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.